ArticleDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2025
B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer.
Abstract read
In one paragraph
Article in Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Extracellular Vesicles in Cancer: Biomarkers, Mechanisms, and Emerging Diagnostic Technologies.Advanced healthcare materials · 2026Review
- Bioorthogonal Click Chemistry-Enabled Enrichment of Extracellular Vesicles for Integrated Molecular and Functional Liquid Biopsy§.Accounts of chemical research · 2026Article
- Detection of Extracellular Vesicles with Colocalized Surface Markers via a Capture-Release-Capture Strategy for Treatment Monitoring in Ewing Sarcoma.Advanced healthcare materials · 2026Article
- Prognostic and therapeutic roles of B7-H3 and B7-H4 in prostate cancer.Discover oncology · 2026Review
- Dynamic Targetable Extracellular Vesicle Surface Proteins Monitor Depth of Response to CAR T Therapy.Research square · 2026Article
- Identification and diagnostic evaluation of an aptamer targeting prostate-cancer-derived small extracellular vesicles.Molecular therapy. Nucleic acids · 2026Article
- Review
- Extracellular vesicles as mediators of prostatic diseases: connecting function to diagnostic and therapeutic applications.Extracellular vesicles and circulating nucleic acids · 2026Review
- Integrated radio-theranostics using a [Theranostics · 2026Article
- Tumor Extracellular Vesicle Digital Scoring Assays for Cancer Detection and Monitoring.Precision chemistry · 2025Review
- Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.Molecular cancer · 2025Review
- Extracellular vesicles in age-related diseases: disease pathogenesis, intervention, and biomarker.Stem cell research & therapy · 2025Review
- Research progress of B7-H3 in malignant tumors.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Yong JuCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: YJu@mednet.ucla.edu.
Joshua WatsonDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: Joshua.Watson@csmns.org.
Jasmine J WangDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: jasmine.jiemei.wang@gmail.com.
Ying-Tzu YenDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: YYen@mednet.ucla.edu.
Lilit GevorkianDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: lilit.gevorkian2@cshs.org.
Zijing ChenDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: zijing.chen@cshs.org.
Kai Han TuDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: kaihan.tu@cshs.org.
Brenda SalumbidesDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: brenda.salumbides@cshs.org.
Aaron PhungCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: aaronphung13@gmail.com.
Chen ZhaoCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: ChenZhao@mednet.ucla.edu.
Hyoyong KimCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: HyoyongKim@mednet.ucla.edu.
You-Ren JiCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: YouRenJi@mednet.ucla.edu.
Ryan Y ZhangCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: RYZhang@mednet.ucla.edu.
Junseok LeeCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: JunseokLee@mednet.ucla.edu.
Jun GongDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: Jun.Gong@cshs.org.
Kevin ScherDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: kevin.scher@csms.org.
Sungyong YouCedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Urology, Cedars-Sinai Medical Center, Los Angeles CA 90048, USA; Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles 90048, USA. Electronic address: Sungyong.You@cshs.org.
Jie-Fu ChenDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: chenj14@mskcc.org.
Hsian-Rong TsengCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: HRTseng@mednet.ucla.edu.
Yazhen ZhuCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Electronic address: YazhenZhu@mednet.ucla.edu.
Edwin M PosadasDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Urology, Cedars-Sinai Medical Center, Los Angeles CA 90048, USA. Electronic address: Edwin.Posadas@csmc.edu.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MHCC EV Digital Scoring Assay for assessing treatment response in HCC patientsR01CA253651 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2020 to 2024
$3.3MExtracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular CarcinomaR01CA255727 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHU, YAZHEN · 2021 to 2025
$3.2MA blood test to identify prostate cancer patients at risk for visceral metastasisR01CA218356 · NCI · CEDARS-SINAI MEDICAL CENTER · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2017 to 2021
$3.0MNovel circulating biomarker digital scores for assessing treatment response in liver cancerR21CA280444 · NCI · CEDARS-SINAI MEDICAL CENTER · PI YANG, JU DONG, ZHU, YAZHEN · 2023 to 2023
$436kNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA218356NCI NIH HHS R01 CA253651NCI NIH HHS R01 CA255727NCI NIH HHS R21 CA280444
Abstract
backgroundB7-H3 is a promising target for cancer therapy, notably in prostate cancer (PCa), particularly in metastatic, castration-resistant PCa (mCRPC). With the development of B7-H3-targeted therapies, there is a need for a rapid, reliable, and cost-effective method to detect and monitor B7-H3 expression. Leveraging their abundance and stability, we developed a liquid biopsy assay using extracellular vesicles (EVs) for this purpose.
methodsB7-H3
resultsThe assay detected higher B7-H3
conclusionsThis B7-H3
Indexed as
B7 AntigensBiomarkers, TumorExtracellular VesiclesProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAgedHumansLiquid BiopsyMaleMiddle AgedB7 AntigensBiomarkers, TumorCD276 protein, humanDiagnosticsExtracellular vesiclesLiquid biopsyProstate cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.